39 research outputs found
Gothic Revival Architecture Before Horace Walpole's Strawberry Hill
The Gothic Revival is generally considered to have begun in eighteenth-century Britain with the construction of Horace Walpoleâs villa, Strawberry Hill, Twickenham, in the late 1740s. As this chapter demonstrates, however, Strawberry Hill is in no way the first building, domestic or otherwise, to have recreated, even superficially, some aspect of the form and ornamental style of medieval architecture. Earlier architects who, albeit often combining it with Classicism, worked in the Gothic style include Sir Christopher Wren, Nicholas Hawksmoor, William Kent and Batty Langley, aspects of whose works are explored here. While not an exhaustive survey of pre-1750 Gothic Revival design, the examples considered in this chapter reveal how seventeenth- and eighteenth-century Gothic emerged and evolved over the course of different architectsâ careers, and how, by the time that Walpole came to create his own Gothic âcastleâ, there was already in existence in Britain a sustained Gothic Revivalist tradition
Tracy Hartley Promo
Promo for Tracy Hartley\u27s art exhibit.
Designed by Emmaline Poehttps://jagworks.southalabama.edu/flyers/1021/thumbnail.jp
Recommended from our members
AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients
Using MRI techniques, we show here that normalization of tumor vessels in recurrent glioblastoma patients by daily administration of AZD2171âan oral tyrosine kinase inhibitor of VEGF receptorsâhas rapid onset, is prolonged but reversible, and has the significant clinical benefit of alleviating edema. Reversal of normalization began by 28 days, though some features persisted for as long as four months. Basic FGF, SDF1α, and viable circulating endothelial cells (CECs) increased when tumors escaped treatment, and circulating progenitor cells (CPCs) increased when tumors progressed after drug interruption. Our study provides insight into different mechanisms of action of this class of drugs in recurrent glioblastoma patients and suggests that the timing of combination therapy may be critical for optimizing activity against this tumor